期刊文献+

血小板增多症患者基因突变与临床特点的关系研究

下载PDF
导出
摘要 目的探究血小板增多症(ET)患者基因突变情况及其与临床特点的关系。方法对2012年1月至2015年1月间于我院确诊的35例ET患者进行回顾性分析和随访,分析不同突变类型患者血常规指标和血栓发生风险的差异。结果 35例ET患者共检出JAK2突变20例,CALR突变10例,MPL突变1例以及三阴性突变4例。不同突变状态下患者的Hb、WBC和Neu水平间无明显差异(P>0.05);JAK2突变患者的Plt水平明显高于CALR突变和三阴性患者(P<0.05)。JAK2突变患者发生血栓事件的风险为非JAK2突变患者的3.121倍(HR=3.121,95%CI:1.082~7.682,P=0.028)。结论不同基因突变的ET患者临床特点间存在差异;JAK2突变的ET患者血栓发生风险明显高于非JAK2突变。
作者 谢晓玲
出处 《哈尔滨医药》 2018年第1期53-54,共2页 Harbin Medical Journal
基金 惠州市科技计划项目(20160801)
  • 相关文献

参考文献2

二级参考文献38

  • 1Fu R, Xuan M, Lv C, et al. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocy-themia (IPSET-thrombosis) in a large cohort of Chinese patients [J]. Eur J Haematol, 2014,92(6): 502-509.
  • 2Lekovic D, Gotic M, Sefer D, et al. Predictors of Survival and Cause of Deathin patients with Essential Thrombocythemia [J]. Eur J Haematol, 2015 : 1-6.
  • 3Tefferi A. mutant molecules of interest in myeloproliferative neoplasms: introduction [J]. Acta Haematol, 2008,119 (4) : 192-193.
  • 4Alvarez-Larran A, Cervantes F, Pereira A, et al. observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia [J]. Blood, 2010,116 (8) : 1205-1210.
  • 5Michiels JJ, Berneman Z, Schroyens W, et al. plateletmediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and throm-botic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia [J]. Platelets, 2006,17(8):528-544.
  • 6Pascale S, Petrucci G, Dragani A, et al. aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target [J]. Blood, 2012,119 (15) : 3595-3603.
  • 7Passamonti F, Rumi E, Randi ML, et al. aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies [ J ]. J Thromb Haemost, 2010,8 (2) : 411 - 413.
  • 8Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia : 2015 update on diagnosis, risk-stratification and management [J]. Am J Hematol, 2015,90(2) : 162-173.
  • 9Tefferi A, Smock KJ, Divgi AB. polycythemia vera-associated acquired yon willebrand syndrome despite near-normal platelet count [J]. Am J Hematol,2010,85(7) :545.
  • 10Kayacioglu I, Gunay R, Saskin H, et al. the role of elopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation [J]. Heart Surg Forum, 2008,11 (3) : 152-157.

共引文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部